Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells

Immunology Letters

Volumn 125, Issue 2, 2009, Pages 129-136

  Silva, Hernandez M ^a,b,c   Vieira, Pedro M M M ^b,c   Costa, Patricia L N ^a   Pimentel, Bárbara M S ^a   Moro, Ana M ^c,d   Kalil, Jorge ^b,c   Maranhão, Andrea Q ^a,c   Coelho, Verônica ^b,c   Brigido, Marcelo M ^a,c  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Millennium Institute   (Brazil)

^d INSTITUTO BUTANTAN   (Brazil)

Author keywords

Anti CD3; Antibody engineering; Antibody humanization; CD3; IL 10

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; OKT 3; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CELL CULTURE; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; MALE; MITOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MUROMONAB-CD3; ORGAN TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 68149172764     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.06.009     Document Type: Article

References (39)

1. Cosimi A.B., Burton R.C., Colvin R.B., Goldstein G., Delmonico F.L., LaQuaglia M.P., et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32 (1981) 535-539
2. Group OMTS. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 313 (1985) 337-342
3. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3 (2003) 123-132
4. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., and Chatenoud L. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 104 (2007) 6335-6340
5. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9 (2003) 1202-1208
6. Friend P.J., Hale G., Chatenoud L., Rebello P., Bradley J., Thiru S., et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68 (1999) 1632-1637
7. Woodle E.S., Xu D., Zivin R.A., Auger J., Charette J., O'Laughlin R., et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68 (1999) 608-616
8. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174 (2005) 4525-4534
9. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
10. Utset T.O., Auger J.A., Peace D., Zivin R.A., Xu D., Jolliffe L., et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29 (2002) 1907-1913
11. Nicolls M.R., Aversa G.G., Pearce N.W., Spinelli A., Berger M.F., Gurley K.E., et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 55 (1993) 459-468
12. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
13. Riechmann L., Foote J., and Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol 203 (1988) 825-828
14. Caldas C., Coelho V., Kalil J., Moro A.M., Maranhao A.Q., and Brigido M.M. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen. Mol Immunol 39 (2003) 941-952
15. Bairoch A., and Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res 28 (2000) 45-48
16. Pearson W.R. Flexible sequence similarity searching with the FASTA3 program package. Methods Mol Biol 132 (2000) 185-219
17. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25 (1997) 3389-3402
18. Higgins D.G., Thompson J.D., and Gibson T.J. Using CLUSTAL for multiple sequence alignments. Methods Enzymol 266 (1996) 383-402
19. Bernstein H.J. Recent changes to RasMol, recombining the variants. Trends Biochem Sci 25 (2000) 453-455
20. Kabat E.A., Wu T.T., Perry H.M., Gottesmann K.S., and Foeller C. Sequences of proteins of immunological interest (1991), Public Health Service, National Institutes of Health, Bethesda, MD
21. Sambrook J., and Russell D.W. Molecular cloning: a laboratory manual (2001), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
22. Andrade E.V., Albuquerque F.C., Moraes L.M., Brigido M.M., and Santos-Silva M.A. Single-chain Fv with Fc fragment of the human IgG1 tag: construction, Pichia pastoris expression and antigen binding characterization. J Biochem 128 (2000) 891-895
23. Lyons A.B., and Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 171 (1994) 131-137
24. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 (2001) e45
25. Caldas C., Coelho V.P., Rigden D.J., Neschich G., Moro A.M., and Brigido M.M. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen. Protein Eng 13 (2000) 353-360
26. Rechavi G., Ram D., Glazer L., Zakut R., and Givol D. Evolutionary aspects of immunoglobulin heavy chain variable region (VH) gene subgroups. Proc Natl Acad Sci USA 80 (1983) 855-859
27. Huber C., Schable K.F., Huber E., Klein R., Meindl A., Thiebe R., et al. The Vκ genes of the L regions and the repertoire of Vκ gene sequences in the human germ line. Eur J Immunol 23 (1993) 2868-2875
28. Costa P.L.N., Fonseca A.S., Souza D.P., Caldas C.A., Coelho V., Moro A.M., et al. Humanization and binding activity of humanized/murine hybrid anti-CD3 scFvs. Mol Cell Proteomics 2 (2003) 760
29. Carpenter P.A., Appelbaum F.R., Corey L., Deeg H.J., Doney K., Gooley T., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 (2002) 2712-2719
30. Li B., Wang H., Dai J., Ji J., Qian W., Zhang D., et al. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116 (2005) 487-498
31. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23 (2005) 1126-1136
32. Hudson P.J., and Souriau C. Engineered antibodies. Nat Med 9 (2003) 129-134
33. Pavlinkova G., Colcher D., Booth B.J., Goel A., Wittel U.A., and Batra S.K. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int J Cancer 94 (2001) 717-726
34. Schwarz M., Rottgen P., Takada Y., Le Gall F., Knackmuss S., Bassler N., et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin αIIβ3 designed by subtractive selection from naive human phage libraries. FASEB J 18 (2004) 1704-1706
35. Zheng D. Antibody gene therapy: an attractive approach for the treatment of cancers and other chronic diseases. Cell Res 17 (2007) 303-306
36. Herrero C., Hu X., Li W.P., Samuels S., Sharif M.N., Kotenko S., et al. Reprogramming of IL-10 activity and signaling by IFN-γ. J Immunol 171 (2003) 5034-5041
37. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
38. + T cells. Eur J Immunol 37 (2007) 129-138
39. Chatenoud L., and Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7 (2007) 622-632